Gilead Sciences | Los Gastos De Explotación



Operating Expenses Cambio Fecha
AbbVie USD 9.61B 6.98B 2025-03
Agios Pharmaceuticals USD 115.35M 20.41M 2025-03
ALKERMES USD 292.72M 25.42M 2025-03
Alnylam Pharmaceuticals USD 576.11M 122.21M 2025-03
Amgen USD 6.86B 85M 2025-03
Biogen USD 2.12B 106.5M 2025-03
BioMarin Pharmaceutical USD 521.25M 64.65M 2025-03
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Eli Lilly USD 7.32B 1.06B 2025-03
Gilead Sciences USD 4.43B 687M 2025-03
GlaxoSmithKline GBP 5.3B 2.12B 2025-03
Glaxosmithkline GBP 7.42B 408M 2024-12
Incyte USD 847.73M 29.46M 2025-03
J&J USD 8.26B 10.37B 2025-03
Merck USD 9.66B 1.67B 2025-03
Moderna USD 1.16B 1.06B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 10.05B 8.12B 2025-03
PTC Therapeutics USD 205.87M 69.79M 2025-03
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Sanofi EUR 8.32B 1.55B 2025-03
Sarepta Therapeutics USD 1.05B 548.51M 2025-03
United Therapeutics USD 411.6M 33.4M 2025-03
Vertex Pharmaceuticals USD 1.89B 230.4M 2024-12



Gilead Sciences Los Gastos De Explotación - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - May 2025.